help-gnu-arch
[Top][All Lists]
Advanced

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[Help-gnu-arch] BNP Paribas / Banking Deal PAII


From: Small-Cap-update
Subject: [Help-gnu-arch] BNP Paribas / Banking Deal PAII
Date: Mon, 6 Dec 2004 09:37:42 -0500 (EST)

BREAKING NEWS HSPACE=0
WIDTH=15
 
 
Related Quote
chart
PAII.OB 0.075 0.00 News

View Detailed Quote
Delayed 20 mins
Quote data provided by Reuters

 
NASDAQ-BB PAII
Natural Resources
Last: 0.075
Change: 0.000
Volume: 199,000
Day High: 0.08
Day Low: 0.06
As of 12/2/04 3:44:00 PM ET 
Press Release - Patch International

( NASDAQ-BB : PAII )


Patch International establishes strategic banking relationship with BNP Paribas one of the world's top banks

December 2, 2004 1:40:00 PM


CALGARY, Dec. 2 / PR Newswire-FirstCall / - Patch International Inc. ( PAII: OTCBB / PQG: Berlin Bremen Stock Exchange ), announced today that BNP Paribas, headquartered in Paris, France, and a world leader in banking and project finance, has become the banking arm for Patch International's energy activities in Algeria.

Patch's president, David Stadnyk, said the banking connection is particularly significant since the European financial giant, with close to 90,000 employees in 84 countries is a specialist in project financing in the energy sector on a long term basis.

"On our recent trip to Algeria, we met with BNP Paribas bankers to explore various ways in which we could work together to participate in the extensive hydrocarbon wealth of the country which is relatively unexplored," he said. "Combined with local knowledge and skilled specialists in the energy sector, BNP Paribas has the financial resources and expertise for successful project financing."

Algeria's current oil reserves are estimated at 15.4 billion bbl (barrels) and its gas reserves are approximately 146.5 TCF (trillion cubic feet).

Meantime, Patch is in negotiations with Sonatrach, the Algerian government's energy corporation to create a joint-venture partnership with the government and First Petroleum Inc., a wholly-owned subsidiary of Patch International Inc.

The First Petroleum team has extensive experience in Algeria and other North African countries in dealing with senior government and industry executives.

ABOUT PATCH INTERNATIONAL

Patch International was a private corporation acquired by publicly traded Praxis Pharmaceuticals early this year. Patch trades under the symbol PAII. It is also listed on the Berlin Bremen Stock Exchange where it trades under the symbol PQG.

In addition to its activities in Algeria, Patch has a major investment interest in Pharmaxis (PXS: Australian Stock Exchange) where it is the company's second largest shareholder with 11.2 million shares. Others include CIBC, HSBC, and the Rothschild Group. Patch is involved in oil and gas projects in Saskatchewan, Texas, and the East Corning area in Northern California.

For further information visit our corporate website at www.patchenergy.com.

    Contact:

    Investor Relations

    Tel: 604-688-2790

    Fax: 604-688-5390

    Email: address@hidden

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made on behalf of the Company. All such forward-looking statements are, by necessity, only estimates of future results and actual results achieved by Patch International Inc. may differ materially from these statements due to a number of factors. Patch International Inc. assumes no obligation to update these forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such statements. You should independently investigate and fully understand all risks before you make investment decisions.




More News From Patch International ( PAII )

Patch's Pharmaceutical Interest Secures US Patent For Multiple Sclerosis Treatment
Wednesday December 1, 9:01 am ET

CALGARY, Dec. 1 / PRNewswire-FirstCall/ - Patch International Inc. (PAII: OTCBB, PQG: Berlin Bremen Stock Exchange) reported that Pharmaxis (PXS: Australian Stock Exchange) has announced that the company has extended the intellectual property protection for its autoimmune disease research, with the grant of a patent by the United States Patent and Trademark Office for a potential new treatment for multiple sclerosis. Patch holds 11.2 million shares in Pharmaxis and is the company's second largest shareholder behind the Rothschild Group.

The patent relates to a series of molecules that inhibit immune cell trafficking which are expected to assist treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.

Multiple sclerosis is a chronic disease of the central nervous system and affects about 1.1 million people in the developed world. Although treatments aimed at delaying the progression of the disease exist, there is no cure.

ABOUT PHARMAXIS

Pharmaxis is a specialist pharmaceutical company committed to the research, development, and commercialization of human therapeutic products for chronic respiratory and autoimmune diseases.

Pharmaxis is focused on the development of its two leading technologies. The first technology includes Bronchitol(TM) and Aridol(TM), which are inhaled non-ionic osmolytes. Bronchitol(TM) is being developed for the treatment of respiratory diseases -- in particular, cystic fibrosis, bronchiectasis, and chronic bronchitis. Aridol(TM) is an improved lung function test and is currently in a 600 subject multicentre Phase III study and over 250 subjects have been enrolled to date.

The second technology focuses on new immune response modifiers -- PXS25 and PXS2000 -- for the treatment of multiple sclerosis and rheumatoid arthritis. The company has a pipeline of products in different stages of development, including four projects at clinical study stage (in patients), two projects in pre-clinical evaluation, and one research project to identify a compound for development.

Pharmaxis operates a first class, TGA-licensed manufacturing facility at Frenchs Forest, near Sydney, Australia.

Pharmaxis was founded in 1998 and is chaired by Denis Hanley, former Chairman and CEO of Memtec Limited. He has extensive experience in growing Australian technology corporations to become successful global entities.

Pharmaxis was listed on the Australian Stock Exchange in November 2003. For additional information on Pharmaxis, please visit the corporate website at www.pharmaxis.com.au.

Patch's Pharmaceutical Interest Files Aridol IND in the USA
Tuesday November 30, 9:02 am ET

CALGARY, Nov. 30 / PRNewswire-FirstCall/ - Patch International Inc. (PAII: OTCBB, PQG: Berlin Bremen Stock Exchange) reported that Pharmaxis (PXS: Australian Stock Exchange) has announced the filing of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA). The IND is the first formal step in conducting a US clinical trial which will support a marketing application for Aridol in the USA in 2005. Patch holds 11.2 million shares in Pharmaxis and is the company's second largest shareholder behind the Rothschild Group.

The Phase III clinical trial will be conducted over ten sites in the US and will recruit 130 subjects. The objective of the trial is to determine sensitivity and specificity of Aridol with respect to clinical diagnosis of Asthma.

Asthma is a public health problem affecting over 20 million people in the USA. The diagnosis and management of asthma is most commonly based on observation of symptoms. New tools are needed that can reduce the cost of asthma on healthcare systems and improve patient well being. In the USA, asthma cost the healthcare system $15 billion last year and 4,500 people died from the condition.

The trial will be conducted in accordance with the International Committee of Harmonisation (ICH) guidelines for Good Clinical Practice (GCP).

Aridol is a patented, inhalable, dry powder that can be administered using a convenient, hand-held device. The test does not require specialist equipment and can be performed in a general practitioner's surgery. It is manufactured by Pharmaxis in the company's TGA-approved facility.

Patch updates global progress
Tuesday November 9, 9:06 am ET

CALGARY, Nov. 9 / PR Newswire-FirstCall/ - Patch International Inc. (PAII: OTCBB, PQG: Berlin Bremen Stock Exchange) is pleased to provide a progress report on its global business activities.

Commenting on the update, Patch president David Stadnyk said,

"It is an exciting time for Patch and we are pleased with the company's progress. Patch continues with its mandate to grow the North American oil and gas revenue stream while moving ever closer to a formal international agreement that would result in significant upside for the company's stakeholders. Just as our pioneering pharmaceutical efforts are coming to fruition, I believe that the coming months will be a period of tremendous success for the company's international oil and gas prospects. Much has happened over the past year, and I want to take this opportunity to update you on these events."

North Africa

Patch has signed a formal agreement with a company operating internationally to develop oil and gas opportunities in North Africa. The partnership with First Petroleum Inc., a private corporation headed by international businessman Danilo Mancin, will lead to the establishment of a partnership operation specializing in the oil and gas exploration and production activities within the highly lucrative North African markets. The company's initial opportunities are in Algeria and Libya.

Ukraine

Patch continues to await a clear outcome to the presidential elections in Ukraine. With the first round of the Ukrainian presidential elections such a close-run event, the international investment community is closely following proceedings.

Currently the fastest growing economy in the world, both of the leading presidential candidates are stressing that an attractive investment climate is one of their key priorities. Whatever the outcome of the election, all analysts are predicting a major investment boom in Ukraine in 2005. Patch will be focusing exclusively on oil and gas opportunities with Nadra Ukrayny, a subsidiary of government owned Naftogaz.

Patch wishes to advise that the agreement as defined in the Letter of Intent with Greenlab Agronomics Inc. was not negotiated and signed. As such there is no agreement between Greenlab and Patch International Inc. effective July 31, 2004.

North America

Patch is involved in oil and gas projects in Saskatchewan, Texas, and the East Corning area in Northern California. Patch's main focus in North America had been on its assets located in the Kerrobert area in the Province of Saskatchewan, Canada. Patch is currently waiting to see if the Manahuilla Creek project in Texas will be commercially viable.

Australia

Patch holds 11.2 million shares in Pharmaxis and is one of the company's largest shareholders with the Rothschild Group, CIBC and HSBC. On November 3, 2004 Patch reported that Pharmaxis (PXS: Australian Stock Exchange) announced that strong support has enabled the company to raise $16.5 million to give it a cash position of more than $39 million through a fully underwritten placement to Australian institutions and sophisticated investors. The placement replenishes the company's cash funds expended on its successful clinical trials during 2004 and therefore allows Pharmaxis to proceed with a new international Phase III trial for Bronchitol(TM). Also, the Phase III clinical trial of Aridol(TM) achieved its endpoints. The trial was designed to evaluate Aridol as a test for asthma. The positive results mean the company will apply for marketing authorization later this year in Australia, and early in 2005 in Europe. Subject to regulatory approval, sales of Aridol are expected to commence in 2005.

ABOUT PHARMAXIS

Pharmaxis is a specialist pharmaceutical company committed to the research, development and commercialization of human therapeutic products for chronic respiratory and autoimmune diseases.

Pharmaxis is focused on the development of its two leading technologies. The first technology includes Bronchitol(TM) and Aridol(TM), which are inhaled non-ionic osmolytes. Bronchitol(TM) is being developed for the treatment of respiratory diseases - in particular, cystic fibrosis, bronchiectasis and chronic bronchitis. Aridol(TM) is an improved lung function test and is currently in a 600 subject multicentre Phase 111 study and over 250 subjects have been enrolled to date.

The second technology focuses on new immune response modifiers - PXS25 and PXS2000 - for the treatment of multiple sclerosis and rheumatoid arthritis.

The company has a pipeline of products in different stages of development, including four projects at clinical study stage (in patients), two projects in pre-clinical evaluation and one research project to identify a compound for development.

Pharmaxis operates a first class, TGA-licensed manufacturing facility at Frenchs Forest, near Sydney, Australia.

Pharmaxis was founded in 1998 and is chaired by Denis Hanley, former Chairman and CEO of Memtec Limited. He has extensive experience in growing Australian technology corporations to become successful global entities.

Pharmaxis was listed on the Australian Stock Exchange in November 2003. For additional information on Pharmaxis, please visit the corporate website at www.pharmaxis.com.au .

ABOUT PATCH INTERNATIONAL

Patch International was a private corporation acquired by publicly traded Praxis Pharmaceuticals early this year. Patch trades under the symbol PAII. It is also listed on the Berlin Bremen Stock Exchange where it trades under the symbol PQG.

In addition to its major investment interest in Pharmaxis Ltd. (PXS: Australian Stock Exchange) where it is one of the largest shareholders, along with CIBC, HSBC, and the Rothschild Group, Patch is involved in oil and gas projects in Saskatchewan, Texas, and the East Corning area in Northern California. Also, the company is involved globally in Ukraine, where it is in the final stages of talks to develop several oil and gas wells in conjunction with the Ukrainian government.


This email was sent to you from the Stocknewscast.com news room. If you wish to take yourself off ( REMOVE) from our subscription list, please use this link to cancel future deliveries. Thank you.

The Information in a Stocknewscast.com IS A PAID ADVERTISEMENT and is for the viewers information only. Patch International has paid a fee not exceeding $5000.00 in cash or stock to have their corporate information featured once. The corporate information is purely and solely the responsibility of Patch International and it is neither commented upon, researched, or in any manner the responsibility of Stocknewscast.com whose only function is as a supplier of media facilities. Any information provided by the advertisers of Stocknewscast.com, through its media services, is not to be construed as a recommendation or suggestion or offer to buy or sell securities, but is provided purely as an informational media service. Stocknewscast.com. makes no warranties or undertakings as to the accuracy or completeness of this information. All due diligence should be done by the reader or their financial advisor. Investing in securities is speculative and carries risk. Persons who wish to buy or sell securities should only do so in consultation with their registered securities advisers.

Stocknewscast.com

reply via email to

[Prev in Thread] Current Thread [Next in Thread]